MAY 04, 2021 7:00 AM PDT

One Vaccine to Rule Them All

WRITTEN BY: Tara Fernandez

There are currently five variants of concern in the U.S., mutant forms of the COVID-causing coronavirus. These variants have been red-flagged by health authorities due to their ability to spread more easily or cause more severe forms of COVID-19. For now, scientists don’t fully understand if these variants could push back the progress we’ve made with COVID-19 therapies and vaccinations, many of which were designed to target the spike protein from the “original” SARS-CoV-2.

Will the vaccines we have still be effective for future, more problematic SARS-CoV-2 variants? Experiments to answer this question are currently underway. In the meantime, researchers have also been looking into the possibility of developing “pan-virus vaccines” that could shield us against emerging variants as well as related coronaviruses. 

These special vaccines trigger our immune systems to produce broadly neutralizing antibodies, Y-shaped proteins capable of recognizing and eliminating multiple strains of the same virus. Many such antibodies have been naturally produced and isolated from individuals infected by viruses such as HIV. In theory, the right vaccine could elicit a similar protective response in people. The most attractive benefit of such pan-virus vaccines is that they could be manufactured and deployed before the next coronavirus threat emerges.

Encouragingly, scientists have already identified cross-neutralizing antibodies that inactivate different strains of related coronaviruses. In a study published in Science, researchers found hundreds of antibodies from a patient who was previously infected by SARS-CoV, a coronavirus responsible for the SARS outbreak of 2003. Interestingly, nine of the antibodies they found in this donor could neutralize both SARS-CoV and SARS-CoV-2. Most of these targeted the domain of the spike protein that binds to ACE2 on human cells, a step required for viral entry during infection. Some of these antibodies could also neutralize a bat SARS-related virus, indicating that these could form the blueprints for the design of future pan-virus vaccines.

According to a recent commentary by experts in the field, creating these vaccines will be challenging but possible.

“It might not always be possible to obtain the ideal breadth of responses across a whole family of viruses,” wrote the authors. “But compromises can be made, and methods for delivering cocktails of antibodies (two or three, say) and vaccines are becoming feasible.”

 


Sources: Science, Nature.

About the Author
  • Tara Fernandez has a PhD in Cell Biology and has spent over a decade uncovering the molecular basis of diseases ranging from skin cancer to obesity and diabetes. She currently works on developing and marketing disruptive new technologies in the biotechnology industry. Her areas of interest include innovation in molecular diagnostics, cell therapies, and immunology. She actively participates in various science communication and public engagement initiatives to promote STEM in the community.
You May Also Like
JUL 15, 2021
Immunology
Your Immune System Can't Deal With All the Plastic You're Eating
JUL 15, 2021
Your Immune System Can't Deal With All the Plastic You're Eating
Microplastics—tiny fragments of plastic, less than five millimeters in diameter—pollute our environment and, ...
AUG 23, 2021
Cancer
A Safe and Effective Combination Therapy for Advanced Cancer
AUG 23, 2021
A Safe and Effective Combination Therapy for Advanced Cancer
Immunotherapies are emerging as a promising strategy for the treatment of late-stage cancers which currently have m ...
AUG 30, 2021
Cancer
A Hot Approach to CAR T Cells
AUG 30, 2021
A Hot Approach to CAR T Cells
Immunotherapy, a type of treatment that targets a patient’s immune system to enhance the natural ability to attack ...
AUG 31, 2021
Immunology
Convalescent Plasma Therapy for COVID-19 Doesn't Work
AUG 31, 2021
Convalescent Plasma Therapy for COVID-19 Doesn't Work
After encountering an infectious agent, the immune system begins churning out antibodies—Y-shaped warriors that ne ...
OCT 07, 2021
Immunology
A 3D-Printed COVID Vaccine Patch?
OCT 07, 2021
A 3D-Printed COVID Vaccine Patch?
Even the bravest souls can get a little nervous when it comes to rolling up their sleeves and getting a shot. Aichmophob ...
OCT 04, 2021
Health & Medicine
Guillain-Barre Syndrome After COVID-19 Infection
OCT 04, 2021
Guillain-Barre Syndrome After COVID-19 Infection
Researchers with the International GBS Outcome Study (IGOS) investigated newly-diagnosed GBS patients from the beginning ...
Loading Comments...